Less than a tenth of individuals that would benefit from obesity jabs including Wegovy are able to get them, caution the global health agency as it releases its first advice on the medications.
With in excess of 1,000,000,000 people worldwide currently obese, it is urging increased and just access to GLP-1 medication.
According to forecasts, over two billion could be living with obesity by 2030 unless action is taken.
"Our latest guidance recognises that obesity is a lifelong illness that can be treated with thorough and ongoing treatment," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are major barriers to broad availability to the treatments that can aid individuals in losing significant body mass, explains the organization.
Weight-Loss Drug Scarcity
Even in the present best projected case, the supply of these medications might only reach around 100 million people – under 10% of eligible patients, according to the WHO.
The recommendation calls on governments and firms to widen availability, via measures such as licensing agreements.
The intellectual property rights on the active ingredient – the core ingredient of the drug Wegovy – is due to expire in several nations in 2026.
The Way Obesity Injections Operate
The injections mimick a body's own hormone to delay gastric emptying, suppress the appetite and enhance satiety so people eat less.
People commonly begin shedding pounds after several weeks of beginning the once-weekly jabs.
Research indicates users may see weight return within a year of stopping the medication, as their normal food cravings come back.
Being carrying excess weight increases your chance for experiencing diseases, such as type 2 diabetes, heart disease, stroke, and certain malignancies.
Obesity impacts individuals in all nations and was linked to millions of deaths worldwide in 2024, according to the health agency.
